Capricor Therapeutics (CAPR) investor relations material

Regulatory and clinical development

• HOPE-3 phase III trial met primary and key secondary endpoints, showing significant efficacy in upper limb function and cardiac measures for Duchenne muscular dystrophy patients.

• FDA accepted HOPE-3 data, reopening the BLA with a PDUFA date set for August 22, 2026; active discussions on labeling and CMC ongoing.

• The regulatory process is unaffected by ongoing litigation with NS Pharma, as FDA decisions are independent of commercial disputes.

• Five clinical trials consistently demonstrated attenuation of skeletal muscle dysfunction, with HOPE-3 using the updated Performance of the Upper Limb 2.0 as the primary endpoint.

• Long-term safety profile is strong, with no critical adverse events and high patient satisfaction; five-year open label extension data to be presented soon.

Legal and partnership developments

• Legal action was filed against NS Pharma after failed negotiations to restructure a distribution agreement that would have set unsustainable pricing.

• The company plans to independently launch deramiocel, aiming for rapid patient access while litigation proceeds in the background.

• Hopes for a peaceful resolution that would allow both parties to revert to independent commercialization.

Competitive landscape and market positioning

• Deramiocel is positioned as synergistic rather than competitive, with unique anti-inflammatory and anti-fibrotic benefits not matched by other approved therapies.

• The therapy is especially targeted at later-stage, non-ambulant patients who have limited options, and is expected to complement gene therapies and exon-skipping drugs.

• Plans to expand indications to Becker muscular dystrophy, FSHD, limb-girdle, and other related diseases with cardiac complications.